Drug Trial Radar · NCT00322452
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
Last checked: Nov 19, 2026Latest source record: Nov 7, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,329
Actual
Start
Mar 2006
Primary completion
Apr 2008
Study completion Jun 2010
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 8, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority.
Conditions
- Non-Small Cell Lung Cancer
Interventions
GefitinibDrug
oral tablet
CarboplatinDrug
IV
PaclitaxelDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Progression Free Survival (PFS) in MonthsTime frame: Tumour assessments as per RECIST were performed at baseline and then every 42 days ± 7 days from randomization until data cut off (14th April 2008).
Locations
56 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Chengdu, China
Research Site
Hangzhou, China
Research Site
Shanghai, China
Research Site
Fuzhou, Fujian, China
Research Site
Guangzhou, Guangdong, China
Research Site
Wuhan, Hubei, China
Research Site
Nanjing, Jiangsu, China
Research Site
Dalian, Liaoning, China
Research Site
Chongqing, Sichuan, China
Research Site
Hong Kong, Hong Kong
Research Site
Jakarta, Indonesia
Research Site
Solo, Indonesia
Research Site
Surabaya, Indonesia
Research Site
Yogyakarta, Indonesia
Research Site
Semarang, Central Java, Indonesia
Research Site
Malang, East Java, Indonesia
Research Site
Nagoya, Aichi-ken, Japan
Research Site
Okazaki, Aichi-ken, Japan
Research Site
Kashiwa, Chiba, Japan
Research Site
Matsuyama, Ehime, Japan
Research Site
Fukuoka, Fukuoka, Japan
Research Site
Sapporo, Hokkaido, Japan
Research Site
Akashi, Hyōgo, Japan
Research Site
Kobe, Hyōgo, Japan
Research Site
Kanazawa, Ishikawa-ken, Japan
Research Site
Yokohama, Kanagawa, Japan
Research Site
Kumamoto, Kumamoto, Japan
Research Site
Ōmura, Nagasaki, Japan
Research Site
Okayama, Okayama-ken, Japan
Research Site
Izumisano, Osaka, Japan
Research Site
Osaka, Osaka, Japan
Research Site
Sakai, Osaka, Japan
Research Site
Sayama, Osaka, Japan
Research Site
Sunto-gun, Shizuoka, Japan
Research Site
Bunkyo-ku, Tokyo, Japan
Research Site
Koto-ku, Tokyo, Japan
Research Site
Shinjuku, Tokyo, Japan
Research Site
Ube, Yamaguchi, Japan
Research Site
George Town, Malaysia
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.